Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT

BACKGROUND: STEPAUT, an Austrian non-interventional study, evaluated the safety and efficacy of everolimus plus exemestane in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) recurring/progressing on/after nonsteroi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast
Autors principals: Steger, Guenther G., Egle, Daniel, Bartsch, Rupert, Pfeiler, Georg, Petru, Edgar, Greil, Richard, Helfgott, Ruth, Marth, Christian, Öhler, Leopold, Hubalek, Michael, Lang, Alois, Tinchon, Christoph, Haslbauer, Ferdinand, Redl, Andreas, Hock, Karin, Hennebelle, Mathias, Mraz, Bernhard, Gnant, Michael
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7375626/
https://ncbi.nlm.nih.gov/pubmed/32062536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2020.01.035
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars